BGMS

#4899
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.86
0.86
Intervallo Annuale
0.57
6.70
Variazione giornaliera
-3.37%
Variazione Mensile
-1.15%
Variazione di 6 mesi
-10.06%
Variazione Annuale
-85.67%
Chiusura Precedente
0.8 9
Open
0.8 6
Minimo
0.8 6
Massimo
0.8 6
Volume
3
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q2 FY2013

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on May 22, 2013. The filing details the results of the Company's Annual Meeting of Stockholders held on the same date.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.

Material Changes and Voting Results

The following proposals were submitted to stockholders and approved:

  • Director Election (Common Stock): Sir John Banham was elected as a Class 1 director. Votes: 1,605,029 For, 0 Against, 262,857 Withheld.
  • Director Election (Preferred Stock): Gregory T. Hradsky was elected as a Class 1 director. Votes: 208,771 For, 1,600 Against, 100 Abstentions.
  • Independent Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2013. Votes: 7,541,420 For, 80,752 Against, 2,037 Abstentions.
  • Executive Compensation (Say-on-Pay): The advisory vote on named executive officer compensation was approved. Votes: 1,574,333 For, 248,607 Against, 44,946 Abstentions.
  • Compensation Vote Frequency: Stockholders voted to hold the advisory compensation vote every two years. Votes: 1,090,567 for every two years, 384,581 for every year, 295,503 for every three years.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the shareholder vote.

Important Facts for Investors to Verify

  • Confirm the new board composition with the addition of Sir John Banham and Gregory T. Hradsky serving until the 2016 annual meeting.
  • Verify the engagement of Ernst & Young LLP as the auditor for the fiscal year ending December 31, 2013.
  • Note that the frequency of executive compensation advisory votes is set to every two years.
  • Review the proxy statement referenced in the filing for detailed executive compensation data.